FDA Determines Regulatory Review Period for ROTATEQ Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for ROTATEQ, a human biological product, as required by law, following a patent extension application submitted to the Director of Patents and Trademarks at the Department of Commerce.